UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Predictors of switching antipsychotic medications in the treatment of schizophrenia

BMC psychiatry, 2010-09, Vol.10 (1), p.75-75, Article 75

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

BMC psychiatry, 2009-09, Vol.9 (1), p.54-54, Article 54

2009

Link zum Volltext

Verfügbarkeit prüfen

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

BMC psychiatry, 2010-01, Vol.10 (1), p.11-11, Article 11

2010

Link zum Volltext

Verfügbarkeit prüfen

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Headache, 2018-09, Vol.58 (8), p.1225-1235

2018

Link zum Volltext

Verfügbarkeit prüfen

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

BMC medical research methodology, 2012-09, Vol.12 (1), p.142-142, Article 142

2012

Link zum Volltext

Verfügbarkeit prüfen

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

BMC psychiatry, 2011-09, Vol.11 (1), p.152-152, Article 152

2011

Link zum Volltext

Verfügbarkeit prüfen

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Journal of managed care & specialty pharmacy, 2019-01, Vol.25 (1), p.46

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Headache, 2017-10, Vol.57 (9), p.1359-1374

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1163-1171

2008

Link zum Volltext

Verfügbarkeit prüfen

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Cost effectiveness and resource allocation, 2009-05, Vol.7 (1), p.11-11

2009

Link zum Volltext

Verfügbarkeit prüfen

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Journal of managed care & specialty pharmacy, 2018-09, Vol.24 (9), p.921

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

CNS neuroscience & therapeutics, 2016-12, Vol.22 (12), p.970-978

2016

Link zum Volltext

Verfügbarkeit prüfen

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Current medical research and opinion, 2010-10, Vol.26 (10), p.2403-2410

2010

Link zum Volltext

Verfügbarkeit prüfen

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Clinical schizophrenia & related psychoses, 2014-07, Vol.8 (2), p.84

2014

Link zum Volltext

Verfügbarkeit prüfen

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Current medical research and opinion, 2008-05, Vol.24 (5), p.1399-1405

2008

Link zum Volltext

Verfügbarkeit prüfen

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Patient preference and adherence, 2011-01, Vol.5 (default), p.547-554

2011

Link zum Volltext

Verfügbarkeit prüfen

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Journal of clinical psychopharmacology, 2006-12, Vol.26 (6), p.666-667

2006

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Value in health, 2006-03, Vol.9 (2), p.77-89

2006

Link zum Volltext

Verfügbarkeit prüfen

Management of Lower Pole Nephrolithiasis: A Critical Analysis

The Journal of urology, 1994-03, Vol.151 (3), p.663-667

1994

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of bar codes versus handwriting for recording trauma resuscitation events

Annals of emergency medicine, 1993-10, Vol.22 (10), p.1545-1550

1993

Link zum Volltext

Verfügbarkeit prüfen

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Journal of endourology, 1998-10, Vol.12 (5), p.469-475

1998

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Value in health, 2006-09, Vol.9 (5), p.358-358

2006

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Pathology in 470 Consecutive Forensic Autopsies

Journal of forensic sciences, 1990-09, Vol.35 (5), p.1042-1054

1990

Link zum Volltext

Verfügbarkeit prüfen

Financial analysis of an inner-city helicopter service: Charges versus collections

Annals of emergency medicine, 1989, Vol.18 (1), p.21-25

1989

Link zum Volltext

Verfügbarkeit prüfen

Does anybody really know what time it is? Does anybody really care?

Annals of emergency medicine, 1994-05, Vol.23 (5), p.1032-1036

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(39)
Berichte
(1)

Sprache

Englisch
(40)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Female
(24)
Male
(24)
Adult
(23)
Middle Aged
(17)
Adolescent
(10)
Aged
(10)
Antipsychotic Agents - Therapeutic Use
(10)
Schizophrenia
(10)
Schizophrenia - Drug Therapy
(10)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Indiana
(8)
Treatment Outcome
(8)
Emergency Medicine
(6)
Health Care Sciences & Services
(6)
Psychiatry
(6)
United States
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Management of Lower Pole Nephrolithiasis: A Critical Analysis

Accuracy of bar codes versus handwriting for recording trauma resuscitation events

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy

Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment

Cardiac Pathology in 470 Consecutive Forensic Autopsies

Financial analysis of an inner-city helicopter service: Charges versus collections

Does anybody really know what time it is? Does anybody really care?

Suchergebnisse filtern